Investigation Report on China Quetiapine Market, 2010-2019
|発行||China Research and Intelligence||商品コード||296868|
|出版日||ページ情報||英文 30 Pages
|中国のクエチアピン市場の分析 Investigation Report on China Quetiapine Market, 2010-2019|
|出版日: 2015年07月24日||ページ情報: 英文 30 Pages||
WHO estimated that the lifetime prevalence of schizophrenia is about 3.8%-8.4% in the world. According to the statistics published by National Center for Mental Health in 2014, the number of people with mental disorders is above 100 million. Suppose the mainland population was 1368 million, the number of people with schizophrenia shall be about 17.8 million. Symptoms of schizophrenia begin earlier in men than in women and are more common to see in men than in women. The risk of dying young in schizophrenia patients is 2 to 2.5 times that in common people. This is the result of increased physical health problems like cardiovascular, metabolic and epidemic diseases. Take diabetes for example, its incidence among schizophrenia patients is 2-3 times that in common people.
Developed by AstraZeneca plc., quetiapine (under the trade name of Seroquel) is an important drug for the treatment of schizophrenia. Approved by CFDA to treat schizophrenia in 2000, quetiapine was listed in the Catalogue of Drugs for the Basic National Medical Insurance in 2014. Currently, local manufacturers of quetiapine are Hunan Dongting Pharmaceutical Co., Ltd and Suzhou Pharmaceutical Group Co., Ltd. No.1 Pharmaceutical Factory, the former owning relevant patent for quetiapine compound according to CFDA.
Quetiapine develops fast after entering China, sales value reaching CNY 116 million in 2013 and CNY 131 million in 2014 with a year-on-year growth of 12.93% and CAGR reaching 9.72% during the period of 2010-2014. With accelerating pace of life and increased life pressure, the incidence of mental disorder keeps going up, which fosters the vast demand for quetiapine in China. Currenly, Hunan Dongting Pharmaceutical Co., Ltd, Suzhou Pharmaceutical Group Co., Ltd. No.1 Pharmaceutical Factory and AstraZeneca plc. Occupy the majority of market share, among which AstraZeneca plc. Had the largest share of 78.50% for sales value in 2014. As local enterprises have patented quetiapine compound and sold it at a relatively low price, their market share is expected to expand in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: